Quarterly ResultMay 7, 2026, 04:42 PM
PTC Therapeutics Q1 Net Loss $2.8M; Revenue Down 76.8%
AI Summary
PTC Therapeutics reported a net loss of $2.8 million for Q1 2026, a significant decline from a net income of $866.6 million in Q1 2025, primarily due to the absence of a large collaboration payment. Total revenues fell by 76.8% to $272.6 million. Despite the financial downturn, the company announced positive 24-month interim results for votoplam in Huntington's disease, showing a 52% slowing of disease progression, and Novartis commenced a global Phase 3 study for the drug.
Key Highlights
- Q1 2026 net loss of $2.8 million, compared to $866.6 million net income in Q1 2025.
- Total revenues decreased 76.8% to $272.6 million from $1,176.1 million year-over-year.
- Net product revenue increased 47.0% to $225.6 million from $153.4 million year-over-year.
- Collaboration and license revenue fell to $0.1 million in Q1 2026 from $986.2 million in Q1 2025.
- Operating activities used $59.0 million cash, a swing from $870.1 million provided in Q1 2025.
- Votoplam showed 52% slowing of disease progression in Stage 2 HD patients at 10mg dose.
- Novartis commenced global Phase 3 study for votoplam in April 2026.
- FDA issued a complete response letter for vatiquinone NDA, requiring an additional study.